Ben Katz, chief executive officer of Happy Head, holds three degrees from the University of Pennsylvania, including an M.B.A.

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published ...

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in ...

Medications like semaglutide and liraglutide may help to reduce the risk of heart attacks, strokes, and other major adverse ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name ...

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

Semaglutide can rapidly reduce heart attacks and other serious cardiovascular complications in adults with overweight or obesity who have pre-existing cardiovascular disease but not diabetes, ...

New research being presented at this year's European Congress on Obesity (ECO 2025) has found that patients of an online ...